These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19441164)

  • 1. CpG island methylation profiling in human melanoma cell lines.
    Tellez CS; Shen L; Estécio MR; Jelinek J; Gershenwald JE; Issa JP
    Melanoma Res; 2009 Jun; 19(3):146-55. PubMed ID: 19441164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
    Liu S; Ren S; Howell P; Fodstad O; Riker AI
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter methylation status of multiple genes in uveal melanoma.
    Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
    Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
    Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
    Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
    Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
    Xu XL; Yu J; Zhang HY; Sun MH; Gu J; Du X; Shi DR; Wang P; Yang ZH; Zhu JD
    World J Gastroenterol; 2004 Dec; 10(23):3441-54. PubMed ID: 15526363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
    Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
    Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer.
    Topaloglu O; Hoque MO; Tokumaru Y; Lee J; Ratovitski E; Sidransky D; Moon CS
    Clin Cancer Res; 2004 Apr; 10(7):2284-8. PubMed ID: 15073103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
    de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
    Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.
    Juhlin CC; Kiss NB; Villablanca A; Haglund F; Nordenström J; Höög A; Larsson C
    PLoS One; 2010 Mar; 5(3):e9472. PubMed ID: 20208994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.
    Hou P; Liu D; Dong J; Xing M
    Cell Cycle; 2012 Jan; 11(2):286-95. PubMed ID: 22189819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
    Li Z; Zhang H; Yang J; Hao T; Li S
    Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.
    Rastetter M; Schagdarsurengin U; Lahtz C; Fiedler E; Marsch WCh; Dammann R; Helmbold P
    Histol Histopathol; 2007 Sep; 22(9):1005-15. PubMed ID: 17523078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
    Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
    Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.